New once-daily AUSTEDO XR regimen now approved in 6, 12, and 24 mg tablet strengthsAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD) indications1,2AUSTEDO is the only VMAT2 inhibitor with 3-year long-...